Aytu BioPharma Inc (AYTU)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$2.12-3.20%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Aytu BioPharma is improving its operating income, reducing losses from $7.62 million to $4.06 million. The company has strong adoption of its EXXUA product, supporting revenue growth. Analysts expect about 25% revenue growth next year. The stock trades cheaply versus peers with a free cash flow yield of 7%.
Revenue has declined from $15.17 million to $12.41 million recently, showing weak growth. The company remains loss-making with negative operating income. Recent termination of material agreements signals challenges. The stock has fallen 15% from its high and momentum is weak.
The market prices in about 25% revenue growth next year but also expects continued losses. Our fair value near $8.31 reflects a cheap valuation versus peers. We differ by emphasizing the risk that revenue and profitability targets may not be met given recent declines and agreement terminations.
Breaks if: Operating loss worsens beyond -$4.06 million in 2026-Q3
Focus on improving operating income as part of financial performance enhancement.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
AYTU represents a speculative growth investment with a focus on turning around its financial performance. The current thesis state is mixed, with some positive momentum but significant risks ahead.
The market seems to expect a continuation of the company's current performance, which is considered cheap compared to peers. There is a notable expectations gap, indicating that investors may not fully anticipate potential challenges or improvements.
Management has shown a commitment to improving operating income, with some progress noted, though the company remains loss-making. Revenue has declined, suggesting that reversing this trend will be crucial for future performance.
The future of AYTU depends on several factors, including management's ability to launch new products successfully and the overall health of the healthcare sector. Additionally, any cuts to guidance or worsening economic conditions could negatively impact the stock.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
No, our read on the company is unchanged. The risk label changed from "elevated" to "high". Recent financial performance remains steady, holding in the top half of its industry. The market backdrop has shifted to a risk-off environment, impacting growth stocks.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 of last 3 quarters. Operating income improved from -$7.62 million in 2025-Q4 to -$4.06 million in 2026-Q3, indicating progress in cost management. However, the company remains in a negative operating income position, showing limited progress towards profitability.
“Operating income improved from -$7.62 million in 2025-Q4 to -$4.06 million in 2026-Q3.”
“Operating income was -$1.97 million.”
“Operating income was -$1.50 million.”
Breaks if: Adoption of EXXUA weakens or declines materially
Breaks if: Revenue falls below $13.9 million in 2026-Q3
The company aims to enhance revenue growth through strategic initiatives.
Stated in 3 of last 3 quarters. Revenue decreased from $15.17 million in 2025-Q4 to $12.41 million in 2026-Q3, indicating a decline in revenue growth. Despite strategic initiatives, the company has shown limited progress in reversing this trend.
“Revenue was $12.41 million.”
“Revenue was $15.17 million.”
“Revenue was $13.88 million.”
Over the next 1 to 3 years, AYTU's performance will largely depend on execution and external market conditions. Not investment advice.